Age- and sex- differences in efficacy of treatments for type 2 diabetes: Network meta-analysis of aggregate and individual level data

Declarations of interest

John Petrie reports personal fees (via his employing institution) from Merck KGaA (Lectures), research support from Merck KGaA (Grant), personal fees from Novo Nordisk (Lectures/ Advisory) and personal fees from IQVIA (Boehringer Ingelheim Adjudication Committees) - all outside the submitted work. Dr Petrie has received non-financial support as co-CI of a JDRF-funded trial (NCT03899402) from Astra Zeneca (donation of investigational medicinal product to US site only) and Novo Nordisk [donation of investigational medicinal product to UK site only; supplementary financial support (to mitigate a budget cut during the COVID-19 pandemic)].

Robert Lindsey reports Event registration paid for by Novo Nordisk 2021, no personal fees. And is current local PI for SOUL study (Novo Nordisk)- no personal fees.

Amanda Adler’s trials unit is undertaking a trial funded by NovoNordisk. The indication is not diabetes.

Naveed Sattar declares grant funding from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics; consulting fees from Abbott Laboratories, AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Janssen, Menarini-Ricerche, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics, and Sanofi; payment for lectures or presentations from Abbott Laboratories, AbbVie, AstraZeneca, Boeringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk, and Sanofi. All work was unrelated to this manuscript.

All other authors declare no conflicts of interest.